^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

1538 Identification of Robust Predictors for Ibrutinib Response By Multi-Omic Genomics in MYD88 Mutated Waldenstrom’s Macroglobulinemia

Published date:
11/03/2022
Excerpt:
Attainment of a major response at 6 months was strongly associated with expression of WNK2 (p=0.0043), as well as DUSP22, GPER1, TNIK and PRDM15 (all p<0.0001). Long-term PFS correlated with attainment of major response at 6 months for these biomarkers.... By use of comprehensive multi-omic genomics, we identified robust biomarkers for clinical investigation to predict ibrutinib major response at 6 months and long term PFS in MYD88 mutated WM patients that included many regulators of ERK1/2 signaling such as WNK2, GPER1, DUSP22, TNIK and PRDM15.
DOI:
https://doi.org/10.1182/blood-2022-170254